	US 12,329,793 B2
	Modified adenovirus and medicine comprising same
Fumihiro Higashino, Sapporo (JP)
Assigned to National University Corporation Hokkaido University, Hokkaido (JP)
Appl. No. 17/439,184
Filed by National University Corporation Hokkaido University, Sapporo (JP)
PCT Filed Mar. 19, 2020, PCT No. PCT/JP2020/012196 § 371(c)(1), (2) Date Sep. 14, 2021, PCT Pub. No. WO2020/189749, PCT Pub. Date Sep. 24, 2020.
Claims priority of application No. 2019-053895 (JP), filed on Mar. 20, 2019.
Prior Publication US 2022/0152133 A1, May 19, 2022
Int. Cl. A61K 35/761 (2015.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 35/761 (2013.01) [A61P 29/00 (2018.01); A61P 35/00 (2018.01)]

12 Claims

1. A modified adenovirus comprising:

an E1A gene;

an E1A enhancer arranged downstream of the E1A gene; and

an AU-rich element (ARE) introduced into a 3′-untranslated region of the E1A gene or at a position adjacent to the 3′-untranslated region,

wherein the E1A gene is incorporated so that the transcription direction of the E1A gene is reverse to the direction of the nucleic acid sequence of the E1A enhancer,

wherein the distance between the E1A gene 5′-end and the E1A enhancer end closer to the E1A gene is 2,900 bp to 3,200 bp, and

wherein the position adjacent to the 3′-untranslated region is a position that enables a mRNA transcribed from the E1A gene by an RNA polymerase to include the ARE at its 3′-end by the read-through by the RNA polymerase.